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Abstract: AIMS Catheter-directed treatment of acute pulmonary embolism (PE) is technically advancing.
Recent guidelines acknowledge this treatment option for patients with overt or imminent haemodynamic
decompensation, particularly when systemic thrombolysis is contraindicated. We investigated patients
with PE who underwent catheter-directed thrombolysis (CDT) in the German nationwide inpatient co-
hort. METHODS AND RESULTS Data from hospitalizations with PE (International Classification of
Disease code I26) between 2005 and 2016 were collected by the Federal Office of Statistics in Germany.
Patients with PE who underwent CDT (OPS 8-838.60 or OPS code 8-83b.j) were compared with patients
receiving systemic thrombolysis (OPS code 8-020.8), and those without thrombolytic or other reperfu-
sion treatment. The analysis was not prespecified; therefore, our findings can only be considered to be
hypothesis generating. We analysed data from 978 094 hospitalized patients with PE. Of these, 41 903
(4.3%) patients received thrombolytic treatment [systemic thrombolysis in 4.2%, CDT in 0.1% (1175 pa-
tients)]. Among patients with shock, CDT was associated with lower in-hospital mortality compared to
systemic thrombolysis [odds ratios (OR) 0.30 (95% 0.14-0.67); P = 0.003]. Intracranial bleeding occurred
in 14 (1.2%) patients who received CDT. Among haemodynamically stable patients with right ventricular
dysfunction (intermediate-risk PE), CDT also was associated with a lower risk of in-hospital mortality
compared to systemic thrombolysis OR 0.55 [95% confidence interval (CI) 0.40-0.75]; P < 0.001 or no
thrombolytic treatment [0.45 (95% CI 0.33-0.62); P < 0.001]. CONCLUSION In the German nationwide
inpatient cohort, based on administrative data, CDT was associated with lower in-hospital mortality
rates compared to systemic thrombolysis, but the overall rate of intracranial bleeding in patients who
received CDT was not negligible. Prospective controlled data are urgently needed to determine the true
value of this treatment option in acute PE.
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Aims Catheter-directed treatment of acute pulmonary embolism (PE) is technically advancing. Recent guidelines acknow-
ledge this treatment option for patients with overt or imminent haemodynamic decompensation, particularly when
systemic thrombolysis is contraindicated. We investigated patients with PE who underwent catheter-directed




Data from hospitalizations with PE (International Classification of Disease code I26) between 2005 and 2016 were
collected by the Federal Office of Statistics in Germany. Patients with PE who underwent CDT (OPS 8-838.60 or
OPS code 8-83b.j) were compared with patients receiving systemic thrombolysis (OPS code 8-020.8), and those
without thrombolytic or other reperfusion treatment. The analysis was not prespecified; therefore, our findings
can only be considered to be hypothesis generating. We analysed data from 978 094 hospitalized patients with PE.
Of these, 41 903 (4.3%) patients received thrombolytic treatment [systemic thrombolysis in 4.2%, CDT in 0.1%
(1175 patients)]. Among patients with shock, CDT was associated with lower in-hospital mortality compared to
systemic thrombolysis [odds ratios (OR) 0.30 (95% 0.14–0.67); P=0.003]. Intracranial bleeding occurred in
14 (1.2%) patients who received CDT. Among haemodynamically stable patients with right ventricular dysfunction
(intermediate-risk PE), CDT also was associated with a lower risk of in-hospital mortality compared to systemic
thrombolysis fOR 0.55 [95% confidence interval (CI) 0.40–0.75]; P<0.001g or no thrombolytic treatment
[0.45 (95% CI 0.33–0.62); P<0.001].
...................................................................................................................................................................................................
Conclusion In the German nationwide inpatient cohort, based on administrative data, CDT was associated with lower in-
hospital mortality rates compared to systemic thrombolysis, but the overall rate of intracranial bleeding in patients
who received CDT was not negligible. Prospective controlled data are urgently needed to determine the true value
of this treatment option in acute PE.
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Pulmonary embolism (PE) represents an important cause of morbid-
ity and mortality in the European population and around the world.1,2
In patients with acute PE who present with haemodynamic instability,
systemic (intravenous) thrombolysis is a potentially lifesaving treat-
ment option by rapidly restoring pulmonary perfusion and reducing
pulmonary vascular resistance.3,4 However, systemic thrombolytic
treatment also carries a substantial risk of major bleeding, including
life-threatening intracranial haemorrhage.5 These concerns may ex-
plain, at least in part, why only 20–30% of eligible patients with acute
PE undergo systemic thrombolytic therapy.6–8
Catheter-directed thrombolysis (CDT) allows local slow infusion
of a low dose of a thrombolytic agent directly into the pulmonary sys-
tem. It can be performed with or without the use of ultrasound-
emitting devices and has yielded promising results in the treatment of
acute PE.9–12 Current guidelines recommend considering percutan-
eous catheter-directed treatment for patients with high-risk PE, in
whom (systemic) thrombolysis is contraindicated or has failed, or as
rescue thrombolytic therapy for patients with haemodynamic deteri-
oration on anticoagulation treatment.3 However, the level of evi-
dence supporting this recommendation is low, and the interventional
options for PE treatment remain partly controversial due to the rela-
tively small number of patients treated and the lack of adequately
sized trials with clinical outcomes. Because of this, and in order to ad-
dress the need for further evidence from the perspective of popula-
tion research, we investigated the efficacy and safety outcomes of
CDT compared to systemic thrombolysis and conservative treat-
ment (management without thrombolysis or other reperfusion treat-
ment) in the large German nationwide inpatient sample from 2005
to 2016.
Patients and methods
Data source and procedural code
definitions
In the German Diagnosis Related Groups (DRG) system, diagnoses
are coded according to the International Classification of Diseases
and Related Health Problems, 10th Revision with German
Modification (ICD-10-GM), and surgical, diagnostic, and intervention-
al procedures according to the German Procedure Classification
[OPS, surgery and procedures codes (Operationen- und
Prozedurenschlüssel)]. All DRG diagnoses of hospitalized patients in
German hospitals are collected by the Federal Office of Statistics
(Statistisches Bundesamt).
Hospitalized patients diagnosed with PE (ICD code I26) between
the years 2005 and 2016 were included. Patients who underwent
CDT, either without (OPS 8-838.60) or with ultrasound assistance
(OPS code 8-83b.j), were identified and included together in the
‘CDT’ group; these patients were compared with patients who
underwent systemic thrombolysis (OPS code 8-020.8), and with
patients who received neither thrombolytics nor any other reperfu-
sion treatment. Of note, patients who underwent (i) surgical embol-
ectomy (OPS code 5-380.42) or (ii) percutaneous treatment
(thrombus fragmentation, OPS code 8-838.7; or rotational thromb-
ectomy, OPS code 8.838.d0) without thrombolytic drugs at any
dosage were excluded from all analyses in the present study in order
to avoid bias regarding patient selection in view of the small size of
these groups. Patients who received both systemic thrombolysis and
CDTwere also excluded from analysis.
Haemodynamically unstable patients with PE were defined as
those who necessitated cardiopulmonary resuscitation (CPR)
(OPS code 8-77) and/or presented with shock (ICD code R57). The
2019 ESC guideline also include ‘persistent arterial hypotension’ as a
criterion for the definition of haemodynamic instability; however, this
parameter could not be captured in the German nationwide inpatient
sample. For further analysis, haemodynamically unstable patients
were classified into the following subgroups: (i) patients who
necessitated CPR and (ii) patients who presented with shock
but without the need for CPR or mechanical ventilation (OPS codes
8-70 and 8-71).
Study outcomes
The outcomes used for our analysis were all-cause in-hospital
mortality and intracranial bleeding (ICD code I61).
Ethical aspects
Since this study did not involve direct access to data of individual
patients by the investigators, approval by an ethics committee
and informed consent were not required, in accordance with
German law.
Statistical methods
Analyses were performed on our behalf by the Research Data
Center (RDC) of the Federal Statistical Office and the Statistical
Offices of the federal states inWiesbaden, Germany (source: RDC of
the Federal Office of Statistics and the Offices of Statistics of the
states, DRG Statistics 2005–2016, own calculations). Aggregated stat-
istical results were made available to us based on SPSS codes (SPSS
VR
software, version 20.0, SPSS Inc., Chicago, IL, USA), which we had
sent to the RDC to conduct these analyses. Continuous variables are
presented as median and interquartile range (IQR); categorical varia-
bles are provided as absolute numbers and corresponding percen-
tages. Comparison of patients with CDT vs. conservative treatment
(no systemic thrombolysis and no CDT) as well as CDT vs. systemic
thrombolysis was performed using the Mann–Whitney U test for
continuous variables and the Fisher’s exact or v2 test, as appropriate,
for categorical variables. Univariate and multivariate logistic regres-
sion models were performed to investigate the impact of CDT on
the in-hospital mortality in comparison to no thrombolysis and of
CDT in comparison to systemic thrombolysis. Results are presented
as odds ratios (OR) and corresponding 95% confidence intervals
(CIs). We fitted multivariate logistic regression models including the
following covariates chosen based on clinical relevance and no obvi-
ous collinearity: age, sex, cancer (ICD codes C00-C97), coronary ar-
tery disease (ICD code I25), heart failure (ICD code I50), chronic
obstructive pulmonary disease (COPD, ICD code J44), essential ar-
terial hypertension (ICD code I10), diabetes mellitus (ICD codes
E10–E14), chronic renal insufficiency (chronic renal insufficiency
stages 3–5 with glomerular filtration rate <60mL/min/1.73 m2: ICD
codes N18.3, N18.83, N18.84, N18.4, N18.5), surgery during in-
hospital stay (OPS code 5), tachycardia (ICD codes I47 and R000),



















































































































































































































































syncope (ICD code R55), and hypoxia (ICD code J96). The multivari-
ate analyses were extended by adding the Charlson index.
The Charlson index was developed as a weighted index to predict
risk of death within 1 year of hospitalization and contains 19 specific
comorbid conditions.13 Major bleeding was defined as the presence
of intracerebral bleeding (ICD code I61), intraspinal bleeding
(G95.10), haemopericardium (ICD code I23.0), haemoperitoneum
(ICD code K66.1), haemarthrosis (M25.0), and/or transfusion of
blood constituents (OPS code 8-800).14
The software SPSS (SPSS
VR
software, version 20.0, SPSS Inc.)
was used for statistical analysis. P-values of <0.05 (two-sided) were




From 2005 to 2016, a total of 1175 patients with PE underwent CDT
in Germany. The annual incidence rate of use of CDT in hospitalized
patients with PE in Germany was 0.1 cases per 1000 patients per
year. These patients had a median age of 68 years and were hospital-
ized over a median period of 10 days (Table 1). Of patients who
underwent CDT, 52 (4.4%) presented with tachycardia, 44 (3.7%)
with syncope, 865 (73.6%) with right ventricular (RV) dysfunction,
and 155 (13.2%) were coded with shock.
In total, 255 patients (19.1% of the population treated with CDT)
died during hospital stay. Transfusion of erythrocytes was necessary
in 234 (19.9%) of the patients treated with CDT, and 14 (1.2%)
patients suffered an intracranial bleeding event (Table 1).
In-hospital outcomes after catheter-
directed thrombolysis compared to no
thrombolytic treatment
We focused on haemodynamically stable patients with acute PE and
RV dysfunction (corresponding to the definition of intermediate-risk
PE in recent guidelines3), comparing the hospital outcome of patients
who underwent CDT with that of patients who received the current
‘treatment standard’ for this risk category, i.e. anticoagulation alone
without thrombolysis or any other reperfusion modality.3 Patients
with acute PE who underwent CDT were younger [68 (IQR 53–76)
vs. 72 (60–80) years; P<0.001] than patients who received no
thrombolysis. Comorbidities such as active malignancy (7.7% vs.
20.5%; P<0.001), COPD (5.7% vs. 10.5%; P<0.001), or renal insuffi-
ciency (6.0% vs. 7.9%; P=0.016) were more often present in patients
without thrombolysis than in patients treated with CDT, whereas
CDT-treated patients more frequently exhibited parameters suggest-
ing early haemodynamic compromise such as tachycardia (4.4% vs.
2.6%; P<0.001) or syncope (3.7% vs. 2.3%; P<0.001).
In-hospital mortality rates and intracranial bleeding rates in haemo-
dynamically stable patients with PE and RV dysfunction who were
treated with CDT are presented, in comparison to those who
received no thrombolysis and no other reperfusion treatment, in
Figure 1A; patients with RV dysfunction who underwent systemic
thrombolysis are also displayed on this panel for comparison. CDT
was associated with a lower risk of in-hospital mortality compared to
management of PE without thrombolytic treatment [0.45 (95% CI
0.33–0.62); P<0.001]. In parallel, however, CDT also was associated
with a 1.5% intracranial bleeding rate (Figure 1A), which was signifi-
cantly higher compared to that of patients who received no
thrombolytic treatment [0.5%; OR 2.52 (95% 1.30–4.89); P=0.006].
In-hospital outcomes after catheter-
directed thrombolysis compared to
systemic thrombolysis
Of the 41 903 patients with acute PE who received any type of
thrombolytic treatment, those who underwent CDT were slightly
younger [68 (IQR 53–76) vs. 69 (57–77) years; P<0.001] and had a
longer stay in hospital [10 (6–16) vs. 9 (3–16) days; P<0.001] than
the patients who received systemic thrombolysis. The frequency of
comorbidities in each group is shown in Table 1. Right ventricular dys-
function (73.6% vs. 78.6%; P<0.001), and haemodynamic instability
presenting as shock (13.2% vs. 20.7%; P<0.001) or need for CPR
(16.6% vs. 42.4%; P<0.001), all were less frequent in patients who
received CDT in comparison to systemic thrombolysis (Table 1). No
significant differences were observed with regard to the need for
transfusion of erythrocytes, gastrointestinal or intracranial bleeding
events (Table 1).
The in-hospital all-cause mortality rate was high (44.2%) in the en-
tire patient population treated with any thrombolytic approach
(CDT or systemic thrombolysis). In-hospital mortality rates and
intracranial bleeding rates associated with CDT vs. systemic thromb-
olysis are shown in Figure 1A for haemodynamically stable and in
Figure 1B and C for haemodynamically unstable patients with shock or
need for CPR, respectively. In both haemodynamically stable and un-
stable patients, the risk of in-hospital mortality was lower in patients
treated with CDT compared to systemic thrombolysis (Take home
figure). Among unstable patients, a lower risk of in-hospital mortality
was observed in patients with acute PE and shock who were treated
with CDT in comparison to systemic thrombolysis [OR 0.30 (95% CI
0.14–0.67); P=0.003]; in patients who underwent CPR, treatment
with CDT also was associated with a lower risk of in-hospital death
independently from age, sex, and comorbidities (Take home figure).
In patients with shock, no intracranial bleeding events occurred in
the group treated with CDT compared to 1.3% of patients treated
with systemic thrombolysis; in patients who needed CPR, intracranial
bleeding occurred with a similar frequency in both the CDT and the
systemic thrombolysis group (Figure 1B and C). Regarding temporal
trends, in-hospital mortality of haemodynamically unstable patients
with PE decreased significantly from 61.1% in 2005 to 54.1% in 2016
[b -0.92 (95% CI -1.73 to -0.11), P=0.026]. Similarly, the rate of
major bleeding events declined from 50.0% in 2005 to 29.7% in 2016
[b -2.09 (95% CI -4.09 to -0.01), P=0.040] (Supplementary material
online, Figure S1).
Among haemodynamically stable patients with PE and RV dysfunc-
tion, fewer patients treated with CDT died in comparison to those
who received systemic thrombolysis (7.4% vs. 13.8%), along with a
similar rate of intracranial bleeding events (1.5% vs. 1.7%) (Figure 1A).
Accordingly, CDT was associated with a lower risk of in-hospital
mortality compared to a treatment with systemic thrombolysis [OR
0.55 (95% CI 0.40–0.75); P<0.001] independently of age, sex, and
comorbidities (Take home figure).











































































































































In-hospital outcomes after catheter-
directed thrombolysis without ultra-
sound assistance compared to
ultrasound-accelerated thrombolysis
From 2014 to 2016, ultrasound-accelerated CDT was performed in
192 patients with acute PE. In comparison to CDT without
ultrasound-assistance (199 patients), patients treated with
ultrasound-accelerated CDT tended to be younger [66 (IQR 50–78)
vs. 69 (56–79) years; P=0.090] and less frequently exhibited signs of
PE-related haemodynamic compromise such as RV dysfunction or
need for CPR (Supplementary material online, Table S1). In a multi-
variate regression model, ultrasound-accelerated CDT was not asso-
ciated with a significantly lower risk of in-hospital mortality compared
to other CDTmodalities (Supplementary material online, Figure S2).
Major bleeding complications in patients
treated with catheter-directed
thrombolysis
Overall, major bleeding was more frequently documented in patients
treated with CDT who underwent surgery during the hospital stay as
well as in those with cancer, heart failure, or signs of haemodynamic
compromise such as hypoxia, shock, or need for CPR
(Supplementary material online, Table S2). For surgery [OR 5.48
(95% CI 3.79–7.80); P<0.001], cancer [OR 2.31 (95% CI 1.42–3.73);
P=0.001], CPR [OR 3.10 (95% CI 2.22–4.49); P<0.001], and shock
[OR 2.64 (95% CI 1.80–3.61); P<0.001], an independent association
with major bleeding was confirmed by multivariate analysis.
Discussion
In patients with PE and haemodynamic instability, systemic thromb-
olysis may be a lifesaving option.7,8,15However, since this therapeutic
modality is also associated with a significantly increased risk of intra-
cranial or fatal haemorrhage,5 CDT techniques (reviewed in16) have
been developed. Trials with surrogate outcomes and a number of co-
hort studies and registries have yielded promising results in patients
undergoing CDT.9,11,12,17–19
In the present study, the annual incidence rate of CDT in hospital-
ized patients with PE in Germany was 0.1 cases per 1000 patients per
year, which is lower than that reported in the USA (1.1 cases per
1000 patients per year).20 Also, compared to previous data, the in-
hospital mortality rate of patients who underwent CDT in Germany
appears higher than that reported in cohorts from the USA.12,19,21
....................................................................................................................................................................................................................
Table 1 Baseline characteristics and outcomes of 41 903 patients with pulmonary embolism who underwent catheter-








Age (years) 69 (57–77) 68 (53–76) 69 (57–77) <0.001
Sex (female) 21 973 (52.4%) 602 (51.2%) 21 371 (52.5%) 0.407
Comorbidities
Obesity 5754 (13.7%) 178 (15.1%) 5576 (13.7%) 0.155
Coronary artery disease 5329 (12.7%) 188 (16.0%) 5141 (12.6%) 0.001
Surgery during hospital stay 20 405 (48.7%) 587 (50.0%) 19 818 (48.7%) 0.391
Active malignancy 3709 (8.9%) 91 (7.7%) 3618 (8.9%) 0.194
Heart failure 12 191 (29.1%) 279 (23.7%) 11 912 (29.2%) <0.001
Chronic obstructive pulmonary disease 3346 (8.0%) 67 (5.7%) 3279 (8.1%) 0.003
Thrombophilia 475 (1.1%) 17 (1.4%) 458 (1.1%) 0.325
Arterial hypertension 16 552 (39.5%) 504 (42.9%) 16 048 (39.4%) 0.017
Renal insufficiency 3190 (7.6%) 70 (6.0%) 3120 (7.7%) 0.032
Diabetes mellitus 8874 (21.4%) 211 (18.0%) 8663 (21.3%) 0.006
Clinical parameters and adverse events during hospitalization
Hypoxia 21 197 (50.6%) 416 (35.4%) 20 781 (51.0%) <0.001
Syncope 1231 (2.9%) 44 (3.7%) 1187 (2.9%) 0.092
RV dysfunction 32 880 (78.5%) 865 (73.6%) 32 015 (78.6%) <0.001
Gastrointestinal bleeding 735 (1.8%) 15 (1.3%) 720 (1.8%) 0.261
Transfusion of erythrocytes 9026 (21.5%) 234 (19.9%) 8792 (21.6%) 0.184
Major bleeding 9558 (22.8%) 243 (20.7%) 9315 (22.9%) 0.079
Shock 8569 (20.4%) 155 (13.2%) 8414 (20.7%) <0.001
Need for cardiopulmonary resuscitation 17 462 (41.7%) 195 (16.6%) 17 267 (42.4%) <0.001
Outcomes
In-hospital mortality 18 526 (44.2%) 225 (19.1%) 18 301 (44.9%) <0.001
Intracranial bleeding 707 (1.7%) 14 (1.2%) 693 (1.7%) 0.210
CDT, catheter-directed thrombolysis; RV, right ventricular. P values of <0.05 (two-sided) were considered to be statistically significant and were presented in bold letters.



















































































































































































































































However, the populations studied cannot be compared directly, as
the German nationwide inpatient sample includes all documented
interventions by both high-volume and low-volume centres in the
country, and thus, by definition, no centre or patient selection bias
exists. In this regard, it is worth mentioning that the CDT-treated
patients in Germany were, on average, almost 10 years older than
those reported from the USA, which might partly be responsible for
their higher mortality rate.20,22
In view of existing data suggesting that CDT may be effective and
acceptably safe in patients with PE, including those with haemo-
dynamic instability,12,21,23,24 current European guidelines suggest to
consider CDT as an alternative reperfusion option for patients with
high-risk PE, if they have a high bleeding risk and contraindications to
systemic thrombolysis, or if systemic thrombolysis has been attempted
and failed.3 In the present analysis, CDT treatment of patients with
shock was independently associated with a substantially (71%) lower
risk of in-hospital mortality compared to systemic thrombolysis; in fact,
no intracranial bleeding was reported during the hospital stay in
patients with shock who were treated with CDT. However, it needs
to be mentioned as a limitation of such comparisons within our study
population that the available data did not include the exact dose of
systemic thrombolytic treatment in each case.
Systemic thrombolysis is generally not recommended for haemo-
dynamically stable patients with evidence of RV dysfunction (inter-
mediate-risk PE),3 because the risk of life-threatening bleeding
complications appears to outweigh the clinical benefits.25 In this con-
text, CDT may have a potential role in intermediate-risk PE by reliev-
ing the right ventricle at a lower, ‘acceptable’ bleeding risk. In a
randomized controlled trial of 59 haemodynamically stable patients
with PE, parameters of RV function (a surrogate outcome) significant-
ly improved after CDT compared with anticoagulation alone; no
major bleeding complications occurred.9 A prospective cohort study
and a phase 2 randomized trial also yielded promising results on sur-
rogate efficacy outcomes.11,12 In contrast to the low mortality rate
ranging between 0% and 1.7% in the above trials,9,11,12 in the present
nationwide inpatient sample, 7.4% of the haemodynamically stable
patients with RV dysfunction treated with CDT died during hospital-
ization, which may again be related to the differences between the
baseline characteristics of trial vs. ‘real world’ populations. However,
our results also revealed that CDTwas associated with a substantially
lower risk (OR 0.45) of in-hospital mortality compared to manage-
ment of PE without thrombolytic treatment. At the same time, CDT-
treated ‘stable’ patients had a 1.5% intracranial bleeding rate in hos-
pital, compared to a 0.5% rate among those treated with anticoagula-
tion alone.
Our study has a number of limitations that must be kept in mind
when interpreting the results. First, since our results are based on ad-
ministrative data, we cannot exclude misclassification or inconsisten-
cies. Additionally, this analysis of the German nationwide inpatient
sample was not prespecified; therefore, our findings can only be con-
sidered to be hypothesis generating. Second, patients with acute PE,
who are treated or died out of hospital or diagnosed post-mortem,
are not included in the German nationwide inpatient sample. Third,
we were able to study the association between variables registered
during hospitalization, but had no information on their temporal or
causal relationship. Fourth, the German nationwide inpatient sample
does not report long-term outcomes after the discharge from hos-
pital. Fifth, propensity score-based analyses were not performed, be-
cause the German Federal Statistical Office provides only aggregated
data, minimizing the chances of controlling the process of case selec-
tion and matching. Finally, until 2014 no distinction was possible be-
tween ultrasound-accelerated and non-ultrasound-accelerated CDT.
In the present study, patients undergoing ultrasound-accelerated
CDT appeared to have lower death rates compared to patients
treated with CDT without ultrasound assistance, but the differences
could not be confirmed in the multivariate regression model; such
comparisons must be considered explorative and serve for hypoth-
esis generation.
Figure 1 In-hospital mortality and intracranial bleeding rates in
patients with pulmonary embolism and (A) right ventricular dysfunc-
tion, (B) shock, or (C) need for cardiopulmonary resuscitation,
according to the route of administration of thrombolytic treatment.
CPR, cardiopulmonary resuscitation.










































































































































In conclusion, our results obtained in the nationwide patient sam-
ple in Germany, revealed potentially relevant associations between
CDT and outcomes in patients with acute PE. Significant differences,
notably lower mortality rates, were observed both in comparison to
systemic thrombolysis in haemodynamically unstable patients and in
comparison to non-reperfusion treatment in haemodynamically sta-
ble patients with RV dysfunction. On the other hand, we observed a
non-negligible rate of intracranial bleeding in patients who underwent
CDT. Clearly, prospective controlled data from adequately powered
trials with clinical outcomes are now urgently needed to determine
the true value of CDT in acute PE.
Supplementary material
Supplementary material is available at European Heart Journal - Acute
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